Mirum Pharmaceuticals, Inc. MIRM Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Product sales, net by Product | |||||
| Bile Acid Medicines | $161.31M+31.0% | $123.11M+232% | $37.08M— | $0— | |
| Livmarli | $360.01M+68.8% | $213.3M+50.4% | $141.8M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Mirum Pharmaceuticals, Inc. break its business down?
- Mirum Pharmaceuticals, Inc. (MIRM) reports product sales, net by product across 2 parts — Bile Acid Medicines and Livmarli. Each is extracted from the segment footnotes and tracked over time.
- Where does Mirum Pharmaceuticals, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Mirum Pharmaceuticals, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
